丙泊酚与右美托咪定镇静对脓毒性休克患者去甲肾上腺素需求的影响:一项交叉试验
这项前瞻性开放标签交叉研究在ICU纳入38例需要去甲肾上腺素维持平均动脉压、且需丙泊酚联合瑞芬太尼深度镇静(RASS -3至-4)的脓毒性休克患者。先将丙泊酚替换为右美托咪定(0.7 ± 0.2 μg/kg/hr),4小时后测量,再换回丙泊酚,8小时后测量。去甲肾上腺素需求从右美托咪定前0.69 ± 0.72 μg/kg/min降至4小时后0.30 ± 0.25 μg/kg/min,停右美托咪定8小时丙泊酚镇静下回升至0.42 ± 0.36 μg/kg/min(p < 0.005)。结论认为在可比镇静深度下,从丙泊酚换为右美托咪定可减少脓毒性休克患者的儿茶酚胺需求。
要点
- 脓毒性休克深度镇静(RASS -3至-4)患者,丙泊酚换为右美托咪定4小时后去甲肾上腺素需求从0.69 ± 0.72降至0.30 ± 0.25 μg/kg/min。
- 停用右美托咪定、换回丙泊酚8小时后去甲肾上腺素需求回升至0.42 ± 0.36 μg/kg/min(p < 0.005)。
- 右美托咪定剂量为0.7 ± 0.2 μg/kg/hr,换药前后丙泊酚(2.6 ± 1.2 vs 2.6 ± 1.2 mg/kg/hr;p = 0.23)与瑞芬太尼(1.27 ± 0.17 vs 1.27 ± 0.16 μg/kg/hr;p = 0.52)剂量不变。
- RASS评分在右美托咪定前-4(-4至-3)、中-4(-4至-3)、后-4(-4至-4)(p = 0.07),镇静深度可比。
适用人群与场景
- 需要去甲肾上腺素维持平均动脉压、且需丙泊酚联合瑞芬太尼深度镇静(RASS -3至-4)的脓毒性休克患者,共38例,大学医院ICU。
诊断标准与关键阈值
- 镇静深度目标为Richmond Agitation-Sedation Scale评分-3至-4,研究期间维持该范围。
处置流程与药物剂量
- 第一步:在丙泊酚镇静下获取血流动力学、去甲肾上腺素剂量和镇静深度基线数据。
- 第二步:将丙泊酚替换为右美托咪定,输注4小时后获取第二组数据;右美托咪定剂量为0.7 ± 0.2 μg/kg/hr。
- 第三步:换回丙泊酚,停用右美托咪定8小时后获取最终数据。
- 研究期间维持RASS -3至-4;换药前后丙泊酚(2.6 ± 1.2 vs 2.6 ± 1.2 mg/kg/hr;p = 0.23)和瑞芬太尼(1.27 ± 0.17 vs 1.27 ± 0.16 μg/kg/hr;p = 0.52)剂量不变。
研究设计与关键结果
- 前瞻性开放标签交叉研究,38例脓毒性休克患者,在ICU进行;去甲肾上腺素需求从右美托咪定前0.69 ± 0.72 μg/kg/min降至右美托咪定输注4小时后0.30 ± 0.25 μg/kg/min,停右美托咪定8小时丙泊酚镇静下回升至0.42 ± 0.36 μg/kg/min(p < 0.005)。
- 右美托咪定剂量0.7 ± 0.2 μg/kg/hr;换药前后丙泊酚剂量2.6 ± 1.2 vs 2.6 ± 1.2 mg/kg/hr(p = 0.23),瑞芬太尼剂量1.27 ± 0.17 vs 1.27 ± 0.16 μg/kg/hr(p = 0.52)。
- RASS评分:右美托咪定前-4(-4至-3),右美托咪定中-4(-4至-3),右美托咪定后-4(-4至-4)(p = 0.07)。
证据类型、等级与局限
- 证据类型:前瞻性开放标签交叉研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于脓毒性休克需要深度镇静的患者,从丙泊酚换为右美托咪定可在可比镇静深度下减少儿茶酚胺需求。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Propofol-based sedation may increase hemodynamic instability by decreasing vascular tone and venous return. Incremental exogenous catecholamines doses may be required to counteract such effects, aggravating the deleterious effects of sympathetic overstimulation. α-2 adrenergic agonists have been reported to decrease norepinephrine requirements in experimental septic shock. The aim of the present study is to test the hypothesis that switching from sedation with propofol to the α-2 agonist dexmedetomidine may decrease norepinephrine doses in septic shock.
DESIGN: Prospective open-label crossover study.
SETTINGS: University hospital, ICU.
PATIENTS: Thirty-eight septic shock patients requiring norepinephrine to maintain adequate mean arterial pressure and needing deep sedation with propofol and remifentanil to maintain a Richmond Agitation-Sedation Scale score between -3 and -4.
INTERVENTIONS: An initial set of measurements including hemodynamics, norepinephrine doses, and depth of sedation were obtained during sedation with propofol. Propofol was then replaced by dexmedetomidine and a second set of data was obtained after 4 hours of dexmedetomidine infusion. Sedation was switched back to propofol, and a final set of measurements was obtained after 8 hours. A Richmond Agitation-Sedation Scale score between -3 and -4 was maintained during the study period.
MEASUREMENTS AND MAIN RESULTS: Norepinephrine requirements decreased from 0.69 ± 0.72 μg/kg/min before dexmedetomidine to 0.30 ± 0.25 μg/kg/min 4 hours after dexmedetomidine infusion, increasing again to 0.42 ± 0.36 μg/kg/min while on propofol 8 hours after stopping dexmedetomidine (p < 0.005). Dexmedetomidine dosage was 0.7 ± 0.2 μg/kg/hr. Before and after dexmedetomidine infusion, sedative doses remained unchanged (propofol 2.6 ± 1.2 vs 2.6 ± 1.2 mg/kg/hr; p = 0.23 and remifentanil 1.27 ± 0.17 vs 1.27 ± 0.16 μg/kg/hr; p = 0.52, respectively). Richmond Agitation-Sedation Scale was -4 (-4 to -3) before, -4 (-4 to -3) during, and -4 (-4 to -4) after dexmedetomidine (p = 0.07).
CONCLUSIONS: For a comparable level of sedation, switching from propofol to dexmedetomidine resulted in a reduction of catecholamine requirements in septic shock patients.
参考来源
- Morelli A, Sanfilippo F, Arnemann P, et al. The Effect of Propofol and Dexmedetomidine Sedation on Norepinephrine Requirements in Septic Shock Patients: A Crossover Trial. Crit Care Med. 2019. PMID: 30394918. doi:10.1097/CCM.0000000000003520
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。